Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
Sydnexis has raised $45.0M in total funding. The most recent round was Series B. The last funding was announced in August 2021.
Sydnexis's investors include RA Capital Management, Longitude Capital, Medicxi, Visionary Venture Fund, SC Master Fund.
Sydnexis is headquartered in Del Mar, United States.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
Sydnexis is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sydnexis — Funding & Investors." VCBacked, August 10, 2021, https://www.vcbacked.co/company/sydnexis. Accessed September 30, 2026.
VCBacked. (2021). Sydnexis — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/sydnexis
{{cite web |title=Sydnexis — Funding & Investors |url=https://www.vcbacked.co/company/sydnexis |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated